JAZZ250516P175000
- 0.00
- 0.000.00%
Jazz Pharmaceuticals Newsroom
Express News | Jazz Pharmaceuticals Showcases Transformative Data at Asco 2025, Highlighting Advances in Small Cell Lung Cancer, Her2+ Gastroesophageal Cancer and Diffuse Glioma
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix
News On Chimerix Inc. (CMRX) Now Under JAZZ
Express News | Jazz Pharmaceuticals Completes Acquisition of Chimerix
A Closer Look At Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Uninspiring ROE
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $210
Jazz Pharmaceuticals Price Target Maintained With a $210.00/Share by Needham
Jazz Pharmaceuticals Analyst Ratings
UBS Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $166
Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025
Express News | Jazz Pharmaceuticals PLC - to Record $145 Million Pre-Tax Charge in Q1 2025 - SEC Filing
Express News | Jazz Pharmaceuticals- Co's Unit Enters Preliminary Class Settlement Agreement With Class of Indirect Xyrem Purchasers - SEC Filing
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $182
Pharma Stocks up on US Tariff Exemptions but Analyst Flags a $46B Import Cost Risk
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $183
After a Year of 4.3% Returns, Jazz Pharmaceuticals Plc's (NASDAQ:JAZZ) Share Price Drop Last Week May Have Less of an Impact on Institutional Investors
Trump's Medical Tariffs Could Significantly Hurt These European Healthcare Firms